This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
Consumer inquiries increase with news* that Bayer AG set aside over $1.5 billion to cover litigation expenses over claims that Yasmin and Yaz oral contraceptives allegedly caused blood clot risks.
San Diego, CA (PRWEB) March 20, 2013
Resource4thePeople announced today that its lawyers are now investigating claims from women who may have suffered blood clots from the use of the popular birth control pills Yaz and Yasmin.
The announcement comes after numerous women have inquired about the possibility of filing a claim after Bayer AG, the company that manufactures the oral contraceptives, revealed* that $1.5 billion was being set aside for litigation costs over the safety of the pills.
"There have been over 10,000 lawsuits filed by women who claim in their filings that they have suffered serious blood clots from the use of Yasmin and Yaz,*" said Resource4thePeople.
"In Bayer's own annual report it details figures as high as $1 billion in payouts in settlements over these suits and has informed stockholders that $1.5 billion was set aside for litigation costs.
"This news has generated a wave of inquiries from women who are interested in filing a claim and reaching a settlement over these allegations and Resource4thePeople lawyers are now standing by to offer free consultations in these cases."
Women who have filed Yaz and Yasmin blood-clotting lawsuits have claimed that they suffered blood clots, deep vein thrombosis, strokes and pulmonary embolisms as a result of their use of the contraceptives according to allegations contained in their lawsuits.
Reuters News Service just recently reported that in its most recent annual report to shareholder, Bayer AG said that it has reserved $1.5 billion for its legal costs involving Yasmin and Yaz, which resulted in a drop in earnings.*
"Germany's largest drugmaker has already reached agreements to pay $1 billion to settle claims by 4,800 women or their representatives in the United States who say the pills caused blood clots that resulted in heart attacks, strokes and death, the report said," according to the Reuters article. "There are currently 10,000 lawsuits in addition to 1,200 claims that haven't been filed in court, according to the report."
Reuters said that since 2009, Bayer has been hit by a wave of lawsuits claiming that the company knew or should have known of the health risks of the contraceptives and failed to warn users.
Bayer is also facing 13 class actions over the drugs in Canada, according to the article.
There have been so many of these Yaz and Yasmin blood-clotting lawsuits filed over claims of severe health problems that the federal court system has coordinated many of them in what is called a multi-district litigation.
Court records show that this special litigation is now in pre-trial evidence gathering and settlement talks before a federal judge who is overseeing thousands of such lawsuits in Illinois.**
Resource4thePeople said that as more Yaz and Yasmin blood-clotting victims come forward, its lawyers will offer free consultations to women who may have suffered health problems as outlined in an April 10, 2012 FDA warning*** which said:
“The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Drospirenone is a synthetic version of the female hormone, progesterone, also referred to as a progestin. Based on this review, FDA has concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other progestin-containing pills. FDA is adding information about the studies to the labels of drospirenone-containing birth control pills.”
In its announcement the FDA said that “The revised drug labels (Beyaz, Safyral, Yasmin and Yaz) will report that some epidemiologic studies reported as high as a three-fold increase in the risk of blood clots for drospirenone-containing products when compared to products containing levonorgestrel or some other progestins, whereas other epidemiological studies found no additional risk of blood clots with drospirenone-containing products. The labels also will include a summary of the previously released results of an FDA-funded study of the blood clot risk.”
Resource4thePeople said that additional inquiries about Yasmin and Yaz claims are coming in over news about a controversial Canadian case.
As reported by the Canadian Broadcasting Company (CBC) the British Columbia coroner’s office refused an autopsy request by the family of a woman who died from blood clots after being prescribed Yasmin.****
The family then spent $1,200 out of their own pockets and their pathologist found that Yasmin and the woman’s obesity put her at risk of suffering the fatal blood clots, according to the report.****
“According to the CBC the victim’s family is now seeking legal advice to determine whether they will join in the litigation against the manufacturers of Yasmin,” said Resource4thePeople. “This case involves similar allegations to those made in thousands of Yaz and Yasmin lawsuits that have been filed in the United States.
“We are now adding lawyers and legal resources to handle the increased number of inquiries being received as a result of this controversy in British Columbia and other incidents involving Yaz and Yasmin blood clots that have been publicized in the media.”
Many of the inquiries from women who have allegedly suffered serious side effects from their use of Yaz and Yasmin were not aware of the number of law suits that have been filed over blood-clotting problems, said Resource4thePeople.
“We are finding that even in this world of advanced technology and instant information many women are telling us they were not fully informed about the health risks that they may have faced through the use of birth control devices and other medications,” said Resource4thePeople.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/3/prweb10544934.htm